EVALUATION OF RATIONAL USE OF ANTIHYPERTENSIVE DRUGS IN PREGNANT WOMEN WITH SOMATIC PATHOLOGY


N.A. Konyshko, A.V.Krikova

SBEI HPE SSMA of RMPH, Smolensk
The study was aimed to the analysis of rationality of the use of antihypertensive drugs in pregnant women in three subjects of the Central Federal District of the Russian Federation. For this purpose, we conducted an analytical study of regulatory guidelines and documents, and assessment the expert opinions on the use of antihypertensive agents in pregnant women. The results lead to the following conclusion: in the national guidelines for the treatment of arterial hypertension in this category of patients of various countries, preference in the choice of second-line drugs is following: United States - labetalol; WHO experts, Australia - oxprenolol and pindolol; European Union - atenolol, metoprolol, pindolol and oxprenolol; Russian cardiologists -propranolol and atenolol. Experts of Central Federal District showed sufficient, good or very good degree of familiarity with the recommended antihypertensive drugs.

About the Autors


N.A. Konyshko – PhD in Medical Sciences, Associate Professor at the Department of Faculty Therapy SBEI HPE SSMA of RMPH, Smolensk; e-mail: Nkonyshko@yandex.ru;
A.V. Krikova - MD, Associate Professor of at the Department of Management and Economics of Pharmacy SBEI HPE SSMA of RMPH, Smolensk; e-mail: anna.krikova @ mail.ru


Similar Articles


Бионика Медиа